Abstract
This randomized phase II trial studies how well low-dose lenalidomide works compared with
high-dose lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or
optic nerve pathway gliomas that have come back (recurrent), have not responded to treatment
(refractory), or are growing, spreading, or getting worse (progressive). Lenalidomide is
classified as an immunomodulatory drug as it boosts the immune system. It has other potential
anti-tumor effects, for example, it may stop the growth of tumor cells by blocking blood flow
to the tumor. It is not yet known whether low-dose lenalidomide is more or less effective
than high-dose lenalidomide in treating patients with juvenile pilocytic astrocytomas or
optic nerve pathway gliomas.
